Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ALKS vs QLTI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALKS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

ALKS Overall Winner 6-Pillar Tally: ALKS 6 – 0 QLTI Matrix Metrics: ALKS 7 – 3 QLTI

As of Nov 16, 2026, Alkermes Inc. plc (ALKS) is the stronger overall head-to-head candidate over GMO International Quality ETF (QLTI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALKS carries a Unified Composite Score of 32.1/100 (SELL) at $46.53 (133.3x Forward P/E, 11.5% operating margin), whereas QLTI carries 47.8/100 (HOLD) at $28.11 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While QLTI currently prints a higher short-term Unified Composite Score (47.8/100 HOLD vs. ALKS 32.1/100 SELL), ALKS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (11.5% vs. N/A operating margin) and revenue trajectory (+21.8% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALKS vs QLTI
ALKS NASDAQ Head-to-Head Winner
Alkermes Inc. plc
Pharmaceutical Preparations
$46.53
-1.06% 1D
Market Cap $7.9B
TTM Revenue $1.75B
Forward P/E 133.3x
Beta / 30D Vol 0.75β · 26% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 16.0 Fund 39.0 Flow 68.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.5 · SMA20: $45.41 · SMA50: $43.68
QLTI NYSE Arca
GMO International Quality ETF
Institutional Equity
$28.11
-0.81% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.81β · 16% Vol
Unified Composite Score
47.8 / 100 HOLD
Tech 50.0 Fund 35.0 Flow 50.0 Mom 11.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $28.06 · SMA50: $27.31

6-Pillar Scorecard Institutional Category Breakdown (ALKS 6 – 0 QLTI)

Columns: Metric · ALKS · QLTI
1. Valuation Multiples ALKS
Forward P/E 133.3x N/M
Trailing P/E 133.3x N/M
PEG Ratio 1.96x N/M
EV / Revenue 5.0x N/M
2. Growth & Scale ALKS
Revenue Growth (YoY) +21.8% N/A
Earnings Growth (YoY) -81.6% N/A
TTM Revenue (USD) $1.75B N/A
Market Cap $7.9B N/A
3. Profitability & Quality ALKS
Gross Margin 87.0% N/A
Operating Margin 11.5% N/A
Net Profit Margin -0.0% N/A
Return on Equity (ROE) -0.0% N/A
4. Balance Sheet & Cash Flow ALKS
Cash Generation (TTM) $282M EBITDA N/A
Cash Flow Margin 16.1% EBITDA Mgn N/A
Net Cash / Leverage $940M Net Debt (0.84x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALKS
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 54.0% (6th %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ALKS
OpEx & R&D Intensity 75.5% of Rev ($1.32B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALKS (7) vs QLTI (3)
Institutional Metric ALKS QLTI Criterion Row Edge
Market Capitalization
Scale
$7.9B N/A Larger Scale ALKS
Trailing P/E Ratio
Valuation
133.3x N/M Lower Multiple ALKS
Forward P/E Ratio
Valuation
133.3x N/M Lower Multiple ALKS
Revenue Growth (YoY)
Growth
+21.8% N/A Higher Growth ALKS
Operating Margin (TTM)
Profitability
11.5% N/A Higher Margin ALKS
Net Profit Margin
Profitability
-0.0% N/A Higher Margin ALKS
Return on Equity (ROE)
Capital Efficiency
-0.0% N/A Higher ROE ALKS
52-Week Range Position
Momentum
68% ($27–$56) 86% ($24–$29) Stronger Trend QLTI
Beta / 30D Volatility
Risk Regime
0.75β · 26% Vol 0.81β · 16% Vol Lower Realized Risk QLTI
Unified Institutional Score
Composite Signal
32.1 / 100 (SELL) 47.8 / 100 (HOLD) Higher Composite QLTI
Trailing 12M Revenue (USD)
Operating Scale
$1.75B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.96x PEG · 5.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$282M EBITDA ($940M Net Debt (0.84x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALKS +10.03 pp
ALKS: +12.88% · QLTI: +2.85%
3M Horizon QLTI +8.26 pp
ALKS: -5.96% · QLTI: +2.3%
6M Horizon ALKS +16.06 pp
ALKS: +25.11% · QLTI: +9.05%
1Y Horizon ALKS +41.98 pp
ALKS: +50.05% · QLTI: +8.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALKS vs QLTI. Trailing 12-month operating profitability (ALKS 11.5% vs QLTI N/A) and valuation multiples (ALKS 133.3x vs QLTI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ALKS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.75B
Gross Margin87.0%
Op. Margin11.5%
ROE / Fwd P/E-0.0% · 133.3x
QLTI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALKS CONSOLIDATION
101d in phase · OBV ACCUMULATION
Current IV 54.0%
IV Percentile 6th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ALKS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
QLTI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QLTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALKS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $7.9B market capitalization and 11.5% operating margin.
OpEx & R&D Reinvestment 75.5% of Rev ($1.32B)
90D Engineering Disclosures 0 Published
QLTI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALKS vs QLTI Key Questions & Quantitative Answers

As of Nov 16, 2026, Alkermes Inc. plc (ALKS) is the stronger overall head-to-head candidate over GMO International Quality ETF (QLTI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALKS carries a Unified Composite Score of 32.1/100 (SELL) at $46.53 (133.3x Forward P/E, 11.5% operating margin), whereas QLTI carries 47.8/100 (HOLD) at $28.11 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While QLTI currently prints a higher short-term Unified Composite Score (47.8/100 HOLD vs. ALKS 32.1/100 SELL), ALKS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (11.5% vs. N/A operating margin) and revenue trajectory (+21.8% vs. N/A YoY).

ALKS leads the Growth & Scale pillar: ALKS posts +21.8% YoY revenue growth and -81.6% YoY earnings growth on $1.75B TTM revenue (87.0% gross margin, 11.5% operating margin), compared with QLTI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ALKS generates $1.75B in USD-normalized revenue versus N/A for QLTI. In operating R&D and SG&A reinvestment, ALKS deploys 75.5% of Rev ($1.32B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QLTI.

ALKS screens cheaper on headline valuation multiples. ALKS trades at 133.3x Forward P/E, 133.3x Trailing P/E, 1.96x PEG, and 5.0x EV/Revenue (16.1% EBITDA margin), whereas QLTI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALKS (-0.0% ROE) versus QLTI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ALKS carries 54.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 26% Vol realized risk). By comparison, QLTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 16% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.